Fast Five Quiz: HR-Positive/HER2-Negative Breast Cancer

Winston W. Tan, MD


September 14, 2021

Figure 1. Human breast cancer cells growing in culture. The clumps of cancer cells are behaving as they would normally, metastasizing and spreading outward. Magnification: 180×.

According to 2014-2018 data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, the best survival pattern is observed among women with the HR+/HER2- subtype of breast cancer, followed by the HR+/HER2+ subtype and the HR-/HER2+ subtype. The HR-/HER2- subtype, also known as "triple-negative breast cancer," has the worst survival. The total 5-year relative survival is 90.3%.

Although breast cancer subtype affects survival, stage at diagnosis may be the most powerful factor in determining survival outcome. For example, among patients with localized disease, the 5-year relative survival is greater than 91% regardless of subtype. Furthermore, 5-year relative survival in localized triple-negative breast cancer is 91.2% but drops to 12.2% in distant disease.

Learn more about breast cancer subtypes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.